vTv Therapeutics Inc. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- vTv Therapeutics Inc. stock issued during period, value, new issues for the quarter ending 2025-12-31 was $0.00.
- vTv Therapeutics Inc. stock issued during period, value, new issues for the quarter ending 2025-09-30 was $77.48M.
- vTv Therapeutics Inc. stock issued during period, value, new issues for the quarter ending 2024-12-31 was $0.00.
- vTv Therapeutics Inc. stock issued during period, value, new issues for the quarter ending 2024-09-30 was $0.00.
- vTv Therapeutics Inc. stock issued during period, value, new issues for fiscal 2025 was $77.48M, a 53.92% increase from fiscal 2024.
- vTv Therapeutics Inc. stock issued during period, value, new issues for fiscal 2024 was $50.34M.
- vTv Therapeutics Inc. stock issued during period, value, new issues for fiscal 2015 was $104.44M.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $77.48M 10-K · filed 2026-03-10 |
| 2025-09-30 | $77.48M 10-Q · filed 2025-11-06 | |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $50.34M 10-K · filed 2026-03-10 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | |
| 2024-03-31 | $50.34M 10-Q · filed 2025-05-15 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | |
| 2022-06-30 | $5.04M 10-Q · filed 2023-08-11 | |
| 2021-09-30 | $11.69M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | |
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $104.44M 10-K · filed 2018-02-27 |